Michael Szarek
Overview
Explore the profile of Michael Szarek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
6143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Aggarwal R, Bhatt D, Steg P, Miller M, Brinton E, Dunbar R, et al.
J Am Heart Assoc
. 2025 Feb;
14(5):e038656.
PMID: 39968782
Background: The efficacy of icosapent ethyl among patients with very well-controlled baseline low-density lipoprotein cholesterol (LDL-C) is unknown. Methods: In this post hoc analysis of the REDUCE-IT (Reduction of Cardiovascular...
3.
Aggarwal R, Bhatt D, Szarek M, Cannon C, Leiter L, Inzucchi S, et al.
Lancet Diabetes Endocrinol
. 2025 Feb;
PMID: 39961315
Background: Sodium-glucose co-transporter (SGLT)-2 inhibitors have shown consistent benefit in improving heart failure-related outcomes but not ischaemic cardiovascular events such as myocardial infarction or stroke. We assessed if the dual...
4.
Schwartz G, Szarek M, Reijnders E, Jukema J, Bhatt D, Bittner V, et al.
Eur J Prev Cardiol
. 2025 Feb;
PMID: 39921475
Aims: Apolipoprotein (Apo) C3 has been associated with incident coronary heart disease and major adverse cardiovascular events (MACE). Whether ApoC3 levels predict risk in patients with acute coronary syndrome (ACS)...
5.
Schwartz G, Szarek M, Jukema J, Cobbaert C, Reijnders E, Bittner V, et al.
Diabetes Care
. 2025 Feb;
PMID: 39913634
Objective: Previous genetic and clinical analyses have associated lower lipoprotein(a) and LDL cholesterol (LDL-C) with greater risk of new-onset type 2 diabetes (NOD). However, PCSK9 inhibitors such as alirocumab lower...
6.
Zahger D, Schwartz G, Szarek M, Fazio S, Steg P
J Am Coll Cardiol
. 2025 Jan;
85(4):e55.
PMID: 39880549
No abstract available.
7.
Hess C, Daffron A, Nehler M, Szarek M, Cannon C, Hsia J, et al.
Vasc Med
. 2025 Jan;
1358863X241309839.
PMID: 39868915
No abstract available.
8.
Geba G, Chen R, Talapatra K, Brackin T, Mohammadi K, Pordy R, et al.
Am J Prev Cardiol
. 2024 Dec;
20:100900.
PMID: 39687787
Background: Patients with recent acute coronary syndrome (ACS) commonly experience chest pain, which affects quality of life even when not due to recurrence of ACS. This post hoc analysis of...
9.
Nissen S, Wang Q, Nicholls S, Navar A, Ray K, Schwartz G, et al.
JAMA
. 2024 Nov;
332(23):1992-2002.
PMID: 39556769
Importance: Elevated lipoprotein(a) increases the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Objective: To evaluate the effects of zerlasiran, a small-interfering RNA targeting hepatic synthesis of apolipoprotein(a), on...
10.
Bonaca M, Szarek M, Schwartz G
Eur J Prev Cardiol
. 2024 Oct;
31(15):1831-1832.
PMID: 39376014
No abstract available.